Alliances
Bioz, Inc., a Silicon Valley AI data company, is proud to announce at American Association for Immunology in San Diego, a new partnership with primary enzyme producer Worthington Biochemical.
Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care.
Eisai Co., Ltd. and the UK Dementia Research Institute announced the launch of a joint post-doctoral programme to support the advancement of novel dementia research.
The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda’s strategy to pare down debt from its $62 billion acquisition of Shire.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
Sarepta struck a deal with the Research Institute at Nationwide Children’s Hospital for the gene therapy candidate, calpain 3.
Under the terms of the deal, Gilead holds exclusive options to license worldwide rights to specific products directed toward targets coming out of Goldfinch’s proprietary Kidney Genome Atlas.
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
Vericel Corporation announced that it has entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid® in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
PRESS RELEASES